bromodeoxycytidine and Sarcoma

bromodeoxycytidine has been researched along with Sarcoma* in 1 studies

Other Studies

1 other study(ies) available for bromodeoxycytidine and Sarcoma

Article	Year
Evaluation of (131/123)I-5-iodo-2'-deoxycytidine as a novel proliferation probe in a tumor mouse model. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013, Volume: 77 This study evaluated a radioiodinated deoxycytidine analog, (131)I-5-iodo-2'-deoxycytidine ([(131)I]ICdR), as a novel proliferation probe and compared it with (131)I-5-iodo-2'-deoxyuridine ([(131)I]IUdR) in a NG4TL4 sarcoma-bearing mouse model. As an imaging agent, the biological characteristics of [(123)I]IUdR is not satisfactory due to its metabolic instability and short biological half-life in vivo. With [(123)I]ICdR/SPECT it was possible to clearly delineate the tumor lesion at 1h post-injection (tumor-to-muscle ratio 7.74) in tumor-bearing mice. The results of biodistribution were consistent with those observed in scintigraphic imaging. This study demonstrated that [(131)I]ICdR is a more promising SPECT probe than [(131)I]IUdR for imaging proliferation. Topics: Animals; Bromodeoxycytidine; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Iodine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Tissue Distribution	2013

Article

Year

Evaluation of (131/123)I-5-iodo-2'-deoxycytidine as a novel proliferation probe in a tumor mouse model.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013, Volume: 77

This study evaluated a radioiodinated deoxycytidine analog, (131)I-5-iodo-2'-deoxycytidine ([(131)I]ICdR), as a novel proliferation probe and compared it with (131)I-5-iodo-2'-deoxyuridine ([(131)I]IUdR) in a NG4TL4 sarcoma-bearing mouse model. As an imaging agent, the biological characteristics of [(123)I]IUdR is not satisfactory due to its metabolic instability and short biological half-life in vivo. With [(123)I]ICdR/SPECT it was possible to clearly delineate the tumor lesion at 1h post-injection (tumor-to-muscle ratio 7.74) in tumor-bearing mice. The results of biodistribution were consistent with those observed in scintigraphic imaging. This study demonstrated that [(131)I]ICdR is a more promising SPECT probe than [(131)I]IUdR for imaging proliferation.

Topics: Animals; Bromodeoxycytidine; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Iodine Radioisotopes; Isotope Labeling; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Tissue Distribution

2013